N6022 treatment increased plasma cGMP. OVA-sensitized mice were treated with a single i.v. dose of N6022 administered 1 h to 24 h prior to MCh challenge. PBS vehicle was given as a single i.v. dose 24 h prior to MCh challenge. Dosing at 24 h prior to MCh challenge occurred one hour prior to the last OVA challenge on study day 22. Plasma cGMP was assessed via enzyme immunoassay. Bars are the means ± SEM of 5 mice per group. *p < 0.05 for treatment vs. vehicle, One-way ANOVA, Dunnett’s.